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Abstract 
Objectives: Long-term prevention of metastatic disease remains a challenge in locally advanced 
rectal cancer (LARC), and robust pre-treatment prognostic factors for metastatic progression are 
lacking. We hypothesised that circulating tumour specific DNA based on hypermethylation of the 
NPY gene (meth-ctDNA) could be a prognostic marker in the neoadjuvant setting; we examined 
this in a secondary, explorative analysis of a prospective trial. 
Methods: Serum samples were prospectively collected in a phase III trial for LARC. Positivity for 
and fractional abundance of meth-ctDNA in baseline samples were estimated. Overall survival (OS) 
and rate of distant metastases were compared between meth-ctDNA positive and negative 
patients; other prognostic factors were controlled for in multivariate Cox regression. Importance 
of quantitative load was examined by considering the fractional abundance of meth-ctDNA 
relative to total circulating DNA. 
Results: Baseline serum samples were available for 146 patients. Thirty patients had presence of 
meth-ctDNA, with no correlation with cT (p=0.8) or cN (p=0.6) stages. Median follow-up was 10.6 
years for OS and 5.1 years for freedom from distant metastases. Patients with meth-ctDNA had 
significantly worse 5-year OS (47% vs 69%), even when controlling for other prognostic factors 
(HR=2.08, 95% CI 1.23-1.51). This appeared mainly driven by disparity in the rate of distant 
metastases (55% vs 72% at 5 years, p=0.01); HR=2.20 (1.19-4.07, p=0.01) in multivariate analysis. 
Increased quantitative load was highly significant for worse outcomes. 
Conclusions: Meth-ctDNA could be a potential prognostic marker in the neoadjuvant setting and 
may, if validated, identify patients at increased risk of distant metastases. 
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Introduction 
 
Modern multimodality treatment of locally advanced rectal cancer results in excellent local control 
rates, with less than 10% of patients experiencing local disease recurrence with appropriate and 
selective use of neoadjuvant chemoradiotherapy (CRT) (1, 2). Long-term prevention of metastatic 
disease remains a challenge, however. The standard arm in the German CAO/ARO/AIO-04 study 
(3) had a cumulative incidence of distant metastasis of >25%, and despite some reduction with the 
addition of pre- and postoperative oxaliplatin, only a minority of patients benefitted. More 
recently, total neoadjuvant treatment (TNT) has gained popularity, although with limited 
prospective evidence (4-6). With the advent of neoadjuvant systemic treatment intensification, 
robust prognostic factors for metastatic progression are needed at the time of diagnosis to 
support treatment individualisation. The vast majority of the biomarker literature focuses on 
prediction of response to CRT at the time of surgery, though, leaving a clear clinical need for 
better baseline prognostic factors for long-term oncological outcomes (7). 
 
A major focus of clinical and translational cancer research in the last decade has been on the use 
of blood-based, tumour-specific markers, such as circulating tumour-specific DNA (ctDNA) for 
disease characterisation and prognostication (8, 9). Progress in non-metastatic rectal cancer has 
been slow, however, partly as identification of tumour-specific cell-free DNA in blood in non-
metastatic rectal cancer has proven challenging. Cell-free DNA can be found in blood in healthy 
patients (10); thus even though absolute levels of cell-free DNA are usually elevated in cancer 
patients, this might not in itself indicate the presence of ctDNA. The current methods for detection 
of ctDNA generally rely on pre-identification of tumour-specific mutations in tissue, which may 
only be possible for a fraction of patients using traditional screening panels of known mutations 
(11, 12). Additionally, the majority of published studies have depended on surgical specimen 
tissue samples, making the methodology unsuitable for neoadjuvant treatment decisions (12). 
 
Hypermethylation of the neuropeptide Y (NPY) gene has been proposed as a universal marker in 
colorectal cancer (14, 15), as methylation of the NPY gene is highly preferentially expressed in 
colorectal cancer compared to normal tissue (14). Analysis of hypermethylation of the NPY gene in 
circulating tumour specific DNA (meth-ctDNA) by droplet digital PCR may hence allow for 
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detection of ctDNA in non-metastatic rectal cancer patients (16). This has not previously been 
examined in detail in localised rectal cancer, however. 
 
We hypothesised that meth-ctDNA could be a prognostic marker in the neoadjuvant setting and 
examined this in a secondary, explorative analysis of a prospective clinical trial. 
 
 
Materials and methods 
 
Patients took part in a phase III trial of radiotherapy dose escalation for locally advanced rectal 
cancer, for which main trial results have previously been reported (17, 18). In summary, patients 
with MRI-staged T3-4N0-2M0 rectal cancer and threatened circumferential resection margin in the 
lower two-thirds of the rectum were enrolled from 2005 to 2008 in two international centres 
(Denmark and Canada). They received 50.4Gy in 28 fractions with concomitant oral UFT and L-
leucovorin, plus an additional 2x5Gy brachytherapy tumour boost in the experimental arm. Total 
mesorectal excision was performed eight weeks after the end of CRT, and adjuvant chemotherapy 
was delivered at the discretion of the treating physician and according to national guidelines. 
Patients were seen at surgical departments for on-protocol follow-up visits every 6 months for the 
first 3 years and once a year in the fourth and fifth years. Any further follow-up was at the 
discretion of the treating surgeon. All electronic patient records were reviewed at the time of final 
analysis of late trial outcomes (June 2013) to verify reported events and to identify disease relapse 
and death not otherwise reported. No differences between the trial arms were observed at the 
final analysis, for any of the late outcomes considered (18). For the current analysis, overall 
survival data were updated (Oct 2017) using the Danish Cause of Death Register. The trial protocol 
was approved by the research ethics committee for the Region of Southern Denmark (protocol ID 
VF20050006), the study was conducted in accordance with the Declaration of Helsinki, and all 
patients provided written informed consent for trial participation and blood sample collection for 
translational research.  
 
Only patients in the Danish part of the trial were involved in the translational sub-study. Baseline 
blood samples were collected in the week prior to start of CRT. Serum was collected in 9 ml tubes, 
left to coagulate for at least 30 minutes and centrifuged at 2000g within 4 hours from sampling. 
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Samples were stored at -80oC until analysis. Serum was centrifuged 10 minutes at 10,000g prior to 
purification. DNA was purified from 2-4 ml serum on a QiaSymphony purification system (Qiagen, 
Hilden, Germany) using the Circulating nucleic acid kit. Fragments of CPP1 DNA were added prior 
to purification as exogenous control (17). DNA was eluted in 60 ul and water added to 400 ul. The 
amount and quality of DNA was determined by qPCR for B2M and CPP1 as previously described 
(19) except that 3 ul of template was analysed per well and a QuantStudio 12k Flex machine 
(Thermo Scientific, Waltham, MA, USA) was used. The remaining DNA was concentrated to 20 ul 
on Amicon Ultra-0.5 Centrifugal Filter Units (Millipore, Burlington, MA, USA). The entire eluate was 
bisulfite converted using EZ DNA Methylation lightning kit (Zymo research, Irvine, CA, USA) 
following the manufacturer’s instructions and eluted in 15 ul. The following controls were included 
in the conversion protocol: water, genomic DNA from non-cancer controls and Universal 
methylated human standard (Zymo research, Irvine, CA, USA) as positive control. Samples and 
controls were analysed by droplet digital PCR together with an additional methylated, bisulfite 
converted control sample EpiTect control DNA, methylated (Qiagen, Hilden, Germany). Twelve ul 
of DNA from samples were mixed with primer/probe mix for NPY and Albumin (sequences from 
Garrigou et al 2016) and Supermix for probes (BioRad, Hercules, CA, USA) in a total volume of 48 
ul. Two-point-five ul of control samples were used. Droplets were prepared on the Auto Droplet 
Generator (BioRad) in two wells with 20 ul per sample. PCR conditions were: 95oC/10 minutes 
followed by 40 cycles of 95oC/15 seconds, 56oC/1 minute and finally 98oC/10 minutes. Ramp rate 
was 1.5oC/second. Droplets were analysed in a QX100 Droplet reader (BioRad). Samples were 
considered positive for meth-ctDNA if >2 positive droplets/sample, and fractional abundance of 
meth-ctDNA was calculated as proportion of meth-ctDNA relative to total amount of circulating 
DNA. Serum analysis was performed blinded to patient outcomes. 
 
The relationship between meth-ctDNA status and baseline disease staging (cT and cN stages) was 
examined using Fisher’s exact test, as was the correlation between meth-ctDNA status and 
primary tumour regression grade (complete or major response, defined as TRG1 or TRG1-2) (20). 
For estimation of overall survival (OS), death from any cause was considered an event, and 
patients were censored if alive at the time of data update (Oct 2017). For estimation of freedom 
from distant metastasis, first incidence of distant metastasis was counted as an event, irrespective 
of any previous locoregional recurrence. Distant metastases were confirmed by either biopsy 
(preferred) or sequential imaging. Patients were censored at time of last clinical assessment prior 
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to final trial data analysis (June 2013). All times were calculated from date of trial enrolment. OS 
and freedom from distant metastases were compared between meth-ctDNA positive and negative 
patients using log-rank tests. Other baseline prognostic factors considered were clinical T and N 
stage as well as age for OS; multivariate Cox regression analysis was used to control for effect of 
these and treatment arm. The importance of quantitative load was examined by considering the 
fractional abundance of meth-ctDNA (i.e. the proportion of meth-ctDNA relative to total amount 
of circulating DNA) in multivariate analysis, controlling for the same factors as above. Based on 
this, five-year OS and freedom from distant metastases were estimated as a function of fractional 
abundance. The proportional hazards assumption was assessed by examination of Schoenfeld 
residuals, and potential non-linear dependence of continuous variables was examined by re-fitting 
models with restricted cubic splines. All analyses were conducted in R version 3.4.1 (R Foundation 
for Statistical Computing, Vienna, Austria).  
 
The REMARK (REporting recommendations for tumour MARKer prognostic studies) checklist was 
followed to ensure complete and transparent reporting (21). 
 
 
Results 
 
Baseline serum samples were available for 146 patients (out of 243 patients treated on trial); 24 
patients were treated outside of Denmark, 71 patients had no baseline blood sample available 
(logistical reasons or samples used in previous research studies), and two patients had no follow-
up data available (consent withdrawn). Table 1 summarises baseline characteristics for the cohort 
included in the current study as well as for all patients treated on trial. Median age was 64 years, 
64% of patients were male, 81% of tumours were T3 (the remaining T4), and 88% of patients were 
N positive. Twenty-four patients in the current study cohort received adjuvant chemotherapy; 
corresponding to 22%, with 11 in standard arm, 14 in dose escalation arm, and 14 patients with no 
data available. No differences were observed between the current study and the full trial cohort.  
 
Baseline blood sample collection was performed median 6 days (interquartile range, IQR, 6-7 days) 
before commencement of CRT. Thirty patients (20.5%) had detectable meth-ctDNA in baseline 
serum samples (i.e. samples were considered positive for meth-ctDNA), with median fractional 
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abundance in serum positive patients of 1.4‰ (IQR 0.6-3.7‰). We observed no correlation 
between meth-ctDNA and clinical T and N stages: Odds ratio (OR) for meth-ctDNA positivity for T4 
vs T3 was 0.81 (95% confidence interval, CI, 0.22-2.49, p=0.8), and corresponding OR for N+ vs N0 
was 0.63 (95% CI 0.19-2.48, p=0.6). Tumour regression grades in the pathology specimen at 
surgery were 22 TRG1, 18 TRG2, 82 TRG3, and 6 TRG4 (18 patients not assessed); with no 
correlation between meth-ctDNA status at baseline and complete (OR 0.64, 95% CI 0.11-2.49, 
p=0.76) or major (OR 1.13, 95% CI 0.40-3.54, p=1.0) tumour regression. 
 
Median follow-up for OS was 10.6 years (interquartile range, IQR, 9.2-11.5 years), with 75 events 
during follow-up. Median follow-up for freedom from distant metastases was 5.1 years (IQR 3.7-
6.0 years), with 47 events during follow-up. Nine patients experienced locoregional recurrence 
during follow-up, of which three patients had locoregional recurrence as the first event. These 
three events were not included in any of the analyses for the current study. Patients with meth-
ctDNA detectable in serum had significantly worse OS at 5 years (47% vs 69%, p=0.02), Figure 1a, 
and this difference appeared mainly driven by disparity in the rate of distant metastases (55% vs 
72% at 5 years, p=0.01), Figure 1b. The prognostic importance of meth-ctDNA remained strong 
when correcting for other prognostic factors in multivariate analysis, with hazard ratio (HR) of 2.08 
(95% CI 1.23-1.51, p=0.007) for OS and HR 2.20 (95% CI 1.19-4.07, p=0.01) for freedom from 
distant metastases. See Table 2 for full model fit. 
 
Increased quantitative load was highly significant for worse outcomes; p<0.0001 and p=0.001 for 
OS and freedom from distant metastases, respectively. This held true in multivariate analyses, HR 
1.24 (1.13-1.35, p<0.0001) per mille (‰) for OS and HR 1.17 (1.07 – 1.29, p=0.001) per mille for 
freedom from distant metastases; see Table 2. Figure 2 demonstrates the dependence of 5-year 
OS and freedom from distant metastases on quantitative meth-ctDNA load.  
 
None of the multivariate models demonstrated deviation from proportional hazard, and none of 
the continuous variables (age and quantitative meth-ctDNA load) showed signs of non-linearity. 
 
 
Discussion 
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Long-term prevention of metastatic disease remains a problem for locally advanced rectal cancer, 
and identification of patients who might benefit from systemic treatment intensification is 
challenging. The role of ctDNA in this setting is still unclear; this may be partly due to difficulties 
identifying ctDNA in blood when tumour-specific mutations are not readily identifiable in 
diagnostic tissue samples. We hypothesised that ctDNA might be generally detectable using 
hypermethylation of the NPY gene, and that presence of ctDNA in blood samples could be a 
prognostic marker. We tested this hypothesis in a cohort of patients with locally advanced rectal 
cancer, prospectively followed as part of a phase III trial. Our results demonstrated that meth-
ctDNA may be detectable in baseline serum samples in 1 in 5 patients, and that presence of meth-
ctNDA at baseline is a prognostic marker for outcome following chemoradiation and surgery. The 
correlation with survival outcomes appeared mainly driven by risk of metastatic disease; and it 
demonstrated a clear dose-response relationship, where higher quantitative load of meth-ctDNA 
was related to higher risk of death and distant disease progression. 
 
This is, to the best of our knowledge, the first study to detect and assess the prognostic impact of 
pre-treatment meth-ctDNA in localised rectal cancer. The NPY gene encodes for a neuropeptide 
that is involved in a range of physiological processes, including vasoconstrictive effects in colon 
tissue. It is still unclear exactly how it might be involved in colorectal malignancy, although there is 
some indication that it could be related to invasive ability (22). It is evident, however, that 
methylation of the NPY gene is highly preferentially expressed in colorectal cancer compared to 
normal tissue (14, 23). This makes it a promising universal blood-based biomarker for colorectal 
cancer (14, 15, 24), avoiding many of the issues with alternative approaches to ctDNA detection, 
such as reliance on identification of patient-specific tumour mutations. A small number of studies 
of meth-ctDNA have previously focused on the metastatic setting (15, 25), but the importance for 
localised disease has not previously been studied in detail. 
 
If patients with locally advanced rectal cancer at high risk of metastatic progression are to be 
selected for upfront treatment intensification – such as induction, consolidation or intensified 
neoadjuvant chemotherapy (4-6, 26) – prognostic markers must be identifiable at treatment 
baseline. Previous work on ctDNA has primarily examined changes in ctDNA levels during and 
following treatment. In the largest and most involved study to date in this setting, Tie et al 
investigated sequential plasma samples from 159 patients undergoing chemoradiotherapy and 
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surgery, focusing on post-operative ctDNA for risk stratification (27). They were partly dependent 
on surgical tumour specimens for identification of somatic mutations for ctDNA detection. Others 
have focused on non-specific cell free DNA (cfDNA) and change in levels after neoadjuvant 
treatment (28–31). In a recent publication, Schou et al showed correlation between total cfDNA 
levels prior to treatment and long term disease outcome in 123 patients (31). Total cfDNA is 
disease non-specific, though, and may be elevated in patients with non-malignant disease (10). 
Based on the Schou et al study, we conducted a subsequent analysis of our own data, focusing on 
total cfDNA, and found no association with survival outcomes (data not shown).  
 
The current study is, as far as we are aware, the largest publication so far to examining baseline 
ctDNA in localised rectal cancer. A previous study of tumour-specific mutations in cfDNA did not 
manage to demonstrate a relationship between baseline detection of ctDNA and prognosis in 97 
locally advanced rectal cancer patients (8), possibly as too many patients were wild type for 
known KRAS and BRAF mutations. 
 
The current study utilized a ctDNA detection methodology valid for all rectal cancer patients, 
irrespective of identification of patient-specific tumour mutations. Other strengths are systematic 
collection of blood samples and prospective follow-up of patients as part of a phase III trial. 
Conversely, it must be strongly emphasised that the analysis itself was retrospective and 
unplanned, thus purely hypothesis generating. Due to the timeframe of the original study, a 
number of factors known today to (potentially) impact patient prognosis were unavailable in our 
dataset, such as extra-mural venous invasion (EMVI) on diagnostic MRI and carcinoembryonic 
antigen (CEA) levels in serum. Note, however, that pathological factors were deliberately not 
included in the multivariate analysis, as these factors are generally not available at diagnosis, 
where upfront systemic treatment intensification may be of interest. All analyses were conducted 
on serum samples, where plasma today would be the preferred option, to avoid unspecific cfDNA 
from leucocytes (32). Finally, there are clearly additional questions to be answered on the 
dynamics of meth-ctDNA load during treatment, post-surgery, and in follow-up, but this was not 
the focus on the current study. 
 
In summary, we have demonstrated that meth-ctDNA can be detected in pre-treatment blood 
samples in patients with locally advanced rectal cancer, and that this could potentially be a 
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prognostic marker for distant disease progression. Our findings will need validation in 
independent datasets, and any predictive value will have to be elucidated before application for 
treatment intensification selection can be considered.  
 
 
Conclusion 
 
Hypermethylation of circulating tumour specific DNA could be a potential prognostic marker in the 
neoadjuvant setting and may, if validated, identify patients at increased risk of distant metastases. 
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Figures 
 
Figure 1: Long term outcomes with/without detectable meth-ctDNA 
Overall survival (a) and freedom from distant metastases (b) for patients with locally advanced 
rectal cancer treated with preoperative chemoradiotherapy. Black curves indicate patients with 
hypermethylated circulating tumour specific DNA (meth-ctDNA) detected in baseline blood serum 
samples; blue curves indicate patients with no meth-ctDNA. 
 
Figure 2: Five-year outcomes as function of fractional abundance of meth-ctNDA 
Five-year overall survival (OS, a) and freedom from distant metastases (b) as function of fractional 
abundance of hypermethylated circulating tumour specific DNA (meth-ctDNA) for an average 
patient (cT3cN1, 64 years old), based on multivariate Cox model. Solid blue lines show model fit, 
while light grey lines represent 95% confidence intervals. 
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Tables 
 
Table 1: Patient characteristics 
 Meth ctDNA cohort 
(n=146) 
Full trial populationぉ 
(n=243) 
Age, years (median, IQR) 64 (57-69) 63 (56-69) 
Gender 
-! Women 
-! Men 
 
53 (36%) 
93 (64%) 
 
87 (36%) 
156 (64%) 
cT 
-! cT3 
-! cT4 
 
118 (81%) 
28 (19%) 
 
204 (84%) 
39 (16%) 
cN 
-! N0 
-! N1-2 
 
18 (12%) 
128 (88%) 
 
26 (11%) 
217 (89%) 
Tumour diameter [cm] 
(median, IQR) 
 
3.5 (3.1-4.1) 
 
3.6 (3.0-4.2) 
Tumour length [cm] 
(median, IQR) 
 
4.8 (4.0-5.6) 
 
4.7 (3.9-5.5) 
Distance to mesorectal 
fascia [mm] (median, IQR) 
 
0 (0-2) 
 
1 (0-2) 
Distance from anal verge 
[cm] (median, IQR) 
 
2.2 (0.5-3.7) 
 
2.4 (0.6-4.0) 
Treatment arm 
-! Standard 
-! Dose escalated 
 
76 (52%) 
70 (48%) 
 
123 (51%) 
120 (49%) 
 
IQR: Interquartile range. Meth-ctDNA: Hypermethylated tumour specific circulating DNA. 
 
  
 15 
Table 2: Multivariate Cox regression analyses 
  OS Distant metastases 
  HR p value HR p value 
Hypermethylation presence    
Meth-ctDNA present 2.08 (1.23 – 3.51) 0.007 2.20 (1.19 – 4.07) 0.01 
cT4 (vs cT3) 1.50 (0.86 – 2.61) 0.15 1.15 (0.56 – 2.33)  0.71 
cN+ (vs cN0) 1.01 (0.50 – 2.06) 0.97 1.26 (0.49 – 3.22) 0.63 
Boost treatment arm 1.34 (0.85 – 2.13) 0.21 1.08 (0.61 – 1.91) 0.81 
Age (continuous)† 1.04 (1.01 – 1.07) 0.02     
Hypermethylation quantitative load    
Meth-ctDNA [‰]* 1.24 (1.13 – 1.35) <0.0001 1.17 (1.07 – 1.29) 0.001 
cT4 (vs cT3) 1.58 (0.91 – 2.76) 0.11 1.22 (0.60 – 2.47)  0.59 
cN+ (vs cN0) 0.89 (0.44 – 1.81) 0.76 1.13 (0.44 – 2.90) 0.80 
Boost treatment arm 1.42 (0.89 – 2.26) 0.14 1.15 (0.64 – 2.06) 0.64 
Age (continuous)† 1.04 (1.01 – 1.07) 0.02     
 
All values in brackets are 95% confidence intervals. Meth-ctDNA: hypermethylated circulating 
tumour specific DNA. NPY: neuropeptide Y. HR: Hazard ratio. OS: Overall survival. *The HR for 
quantitative NPY hypermethylation load represents the change in risk with an increase of one ‰ 
(0.1%) in the fractional abundance of meth-ctDNA in serum cell free DNA. †The HR for age 
represents the change in risk with an increase in age of one year. 
 
 
